2008 Annual Report
This Annual Report covers the SNO 2008 fiscal year, from July 1st, 2007 through June 30, 2008.
A Message from the President

Dear Colleagues and Friends,

In this edition of our annual report, I am proud to be able to share with you some of the accomplishments at SNO over the past year. As we grow as an organization with over 1,000 active members to date, each annual meeting becomes more impressive than the last and 2007’s meeting in Dallas was no exception. There were a record number of attendees and we thank Russell Pieper for arranging a wonderful scientific program and Lois Lampson for leading the education day.

I am pleased to announce some exciting developments for the 2008 meeting in Lake Las Vegas. There were a record number of abstracts submitted and this year’s scientific program will be led by Michael Vogelbaum, who deserves special thanks for organizing this critical component of the Society’s activities. There will be an opening session devoted to the top-scoring abstracts, so all attendees will have a chance to share in the best research being conducted across neuro-oncology sub-specialties. Patrick Wen has done a superb job in coordinating the education day and this will be the first year for a quality-of-life session to be incorporated. This will bring focus to an issue that is fundamental to everyone who treats patients with CNS disease and one that is becoming increasingly relevant as new therapies are developed and survival is prolonged. This initiative is being led by Sherry Fox and we are grateful to the Tug McGraw Foundation for their support of this important session. We will also have the opportunity to recognize the renowned work of Charles Wilson, who will be honored with the Lifetime Achievement Award at this year’s banquet.

In May 2009, the World Federation of Neuro-Oncology will meet in Japan, bringing together members of SNO, the Asian Society of Neuro-Oncology (ASNO), and the European Association of Neuro-Oncology (EANO) and we look forward to a dynamic meeting. In the fall of 2009, SNO will partner with the American Association of Neurological Surgeons and Congress of Neurological Surgeons Joint Section on Tumors to hold a conference in New Orleans. Frederick Lang will represent SNO as co-scientific chair for this meeting along side Randy Jensen of the Joint Section.

I am also happy to share that the impact factor of the Society’s official journal, Neuro-Oncology, continues to rise, solidifying its reputation as the leading journal in the field. Its success is in large part due to the dedication of the Editor-in-Chief, W.K. Alfred Yung, and SNO Editor C. David James, and their efforts at setting high-quality standards for the journal. We would like to thank the SNO membership for continuing to send manuscripts containing significant findings to Neuro-Oncology, which is an essential part of driving the impact factor up. We have recently increased publication from four issues per year to six issues per year to accommodate timely publication of important work.

To continue its mission in promoting the advancement of neuro-oncology through education, SNO has developed several new initiatives aimed at increasing opportunities for junior investigators. These include the opportunities for grant review by senior investigators, mentoring programs, and travel scholarships. The travel scholarship also serves as a mechanism to expand the global presence of SNO and to foster the international relationships that are so enriching to the field.

Another major accomplishment of SNO during the past year has been our success in collaborating with other organizations with similar goals. In addition to our new meeting with the Joint Section on Tumors, we continue to be involved with the coordination of the tumor club at the annual meeting of the American Association for Cancer Research to broaden our base and forge relationships with other scientists. This year we also worked with members of the International Symposium on Pediatric Neuro-Oncology (ISPNO) and contributed to administrative aspects of ISPNO meetings in an effort to support this specialized field. Reports from this year’s annual ISPNO meeting recorded a record number of registrants. The next meeting of ISPNO will be in 2009 in Vienna.

In closing, I would like to acknowledge some of the individuals who have made SNO a success and by extension furthered the development of neuro-oncology as a field. First, much appreciation goes to the SNO Foundation directors Edward Shaw, Mitchel Berger and Victor Levin and members of the Partners Advisory Council for their continued support and guidance as the Society continues to grow. Thanks also to the 2006 – 2007 president Abhijit Guha and vice president Mark Gilbert for their service to SNO and their continued leadership and initiation of successful programs to foster collaboration. I would also like to recognize the members of the Board of Directors for their willingness to represent the diverse disciplines of the Neuro-Oncology community and for their input into critical aspects of operating the Society. Special thanks go to Chas Haynes, Linda Greer, and Jan Esenwein for administrative support, without which we could not be as successful. This team provides the continuity needed to allow smooth transitions between leadership periods and maintains a cohesive infrastructure for the Society.

Willingness to contribute is what makes the Society thrive and I strongly encourage members to take an active role in SNO committees to bring new perspectives and to strengthen the group overall. In addition to shaping our future as a Society, the collaborations and friendships fostered as a result of participation in the Society remind us of why we have chosen this challenging field, keeps us focused on the discovery process for new treatments, and inspires us to learn how to better care for our patients.

Susan M. Chang
SNO President
A Message from the Executive Director

Dear Society Members,

As you will read in the subsequent pages of this report, it has been an eventful year for the Society for Neuro-Oncology. Perhaps if there is one word that sums up the last twelve months, it would be growth. Thanks to the efforts of the SNO leadership, the SNO Foundation and the hard work and dedication of our member volunteers, our Society has expanded on practically every front. Above all, this growth is a testament to the importance of the work being done in the field of neuro-oncology and the urgency for which patients with brain tumors need this work to yield positive results.

Our official journal, Neuro-Oncology, has had another banner year. Under the guidance of Editor-in-Chief W.K. Alfred Yung, the journal’s ISI Impact Factor has increased once again to 5.806, up from 4.939. Not only does this new ranking place Neuro-Oncology ahead of its direct peer neuro-oncology journals, but also establishes it as sixth among all ranked clinical neurology journals and sixteenth among other oncology journals. Paper submissions are also up, and despite the increase from four to six issues per volume year in 2008, we must now seriously consider yet another increase to twelve issues per year in the very near future. Of course an increase in submissions also has an effect on the length of time it takes from submission to print publication, so this year we were pleased to announce that citable versions of accepted papers are now being posted ahead of print on the highwire website. Certainly, the continued success of the journal is a team effort, made possible by the new editorial structure put in place last year which serves to formalize the relationship between the three societies that have adopted Neuro-Oncology as their official journal: SNO, the European Association for Neuro-Oncology (EANO) and the Japan Society for Neuro-Oncology (JSNO). We believe that this change in the editorial structure creates a more equitable and representative relationship for each supporting organization, and SNO thanks executive editors C. David James (SNO), Michael Weller (EANO) and Ryo Nishikawa (JSNO) for representing their respective organizations in this editorial capacity. SNO has recently begun to explore additional ways that all three endorsing organizations can coordinate and increase their level of support for Neuro-Oncology and we look forward to expanding these partnerships in the future.

I am also pleased to report that our 12th Annual Scientific Meeting and Education Day, held in Dallas in November of 2007, was the most successful event in our organization’s history. With Russell Pieper organizing the Scientific Program and Lois Lampson organizing our Education Day, we enjoyed a record number of abstract submissions and broke new records for attendance and sponsorship. A detailed overview of the SNO Annual Meeting can be found further in this report.

Our international outreach efforts also made positive progress in helping to facilitate neuro-oncology education and related activities in areas of the world not currently served by SNO or our sister organizations. Thanks to the generous support of our members, we were able for the first time to offer travel grants to the SNO meeting. This year seven neuro-oncology professionals from developing regions will attend our annual meeting and return to their home country ready to educate their local colleagues. With the leadership of SNO International Committee chair Jonathan Finlay, we look forward to expanding this important initiative.

SNO reached a milestone this year, exceeding 1000 members for the first time in our history. But we shall not stop there. Indeed we are looking for new ways to encourage and nurture the careers of young professionals entering the field. To that end, we started a new initiative to provide young investigators with guidance that will assist them in obtaining their first peer reviewed funding for clinical or basic research. A mentorship program is also in the planning stage and will be officially launched at the 2008 meeting in Las Vegas.

So as we grow and evolve on many fronts, the SNO leadership decided that a new corporate image was needed to reflect the dynamic nature of our organization. Our new logo, which we believe presents a fresh, professional graphic identity for the Society, appears on this page.

Finally, SNO would like to thank our president Susan Chang, whose steady hand at the wheel of the Society has made the progress outlined in this report possible. Abhijit Guha, immediate past-president, whose unbounded energy set the stage for many of the initiatives we are working on today, and of course Jan Esenwein, whose dedication to the Society and hard work has been a consistent factor in our progress this year. As always, we welcome your comments and ideas for additional ways we can build on the accomplishments of 2008.

J. Charles Haynes, JD
SNO Executive Director
Dear Society for Neuro-Oncology
Members and Supporters,

The Society is pleased to provide you with its second annual report. Now in its fourteenth year, the Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

The Society now has four programs—the Annual Meeting Sponsorship Program, the Partner’s Advisory Council, the President’s Club, and the Victor Levin Founder’s Society—which sustain its vision and mission. The Annual Meeting Sponsorship Program has facilitated growth in the Society’s premier education event. Those non-profit associations, foundations and societies, and corporate donors who support the annual meeting at the highest level with a multi-year commitment are members of the Partner’s Advisory Council, which has direct access to the SNO Board of Directors and Foundation Board on a regular basis. Current members of the Council include the American Brain Tumor Association, EMD Serono, Genentech, the National Brain Tumor Society, the Pediatric Brain Tumor Foundation, Schering-Plough Oncology and the Sontag Foundation. The President’s Club provides annual giving opportunities for individual members of the Society. Through endowment, future Society-supported educational and research endeavors of the Society will be funded by the Victor Levin Founder’s Society.

As you read through the pages of this year’s report, consider how you may contribute to the Society with your time or financial resources. Together we are making progress toward the goal of helping our patients live longer and better!

Sincerely,

Victor A. Levin, MD, Mitchel S. Berger, MD
and Edward G. Shaw, MD
The 2007 Society for Neuro-Oncology Scientific Meeting held at the Gaylord Texan Resort in Dallas, Texas, November 15 – 18, was a huge success. The meeting, which drew a record number of abstracts (490, up 16% from 2006) and attendees (over 900, an increase of over 10% from 2006) began Thursday with an Education Day organized by Lois Lampson, PhD, focusing on new targeted therapies for brain tumors. The goal of the day was to consider alternative ways of attacking a defined tumor target. Six speakers — five new to SNO — approached the theme from different viewpoints, then stayed for individual and group discussions.

Jan Reichert (Tufts) spoke about trends in drug development in the pharmaceutical industry. Nancy Lin (Harvard) shared experience with both antibodies and small molecule inhibitors directed against brain metastases.

Bert de Boer (Leiden) described ways of delivering therapeutic agents across the blood-brain barrier. Raja Choudhury (Karolinska) made the case for active, as opposed to passive, immunotherapy. Andre Rogatko (Emory) introduced novel approaches to testing new agents in clinical trials. Ian Pollack (Pittsburgh) gave a neurosurgeon’s perspective on the different approaches. Lois Lampson (Harvard; program chair) was the moderator. The final session was devoted to research funding. Naomi Berkowitz (ABTA), Roy Wu (NCI) and Jane Fountain (NINDS) made brief presentations, then answered questions, from the viewpoint of non-federal and federal agencies, respectively.

The scientific meeting, organized this year by Russell Pieper, PhD, began on Friday with four concurrent and very well-attended Sunrise Sessions focusing on angiogenesis, the blood-brain barrier, medulloblastoma, and meningioma, followed by a Plenary Keynote Address on the Molecular Biology of Pediatric Gliomas by Ian Pollack, MD. The keynote address was followed by a special session devoted exclusively to presentations related to pediatric
The abstracts from the 2007 meeting were published in a special issue of *Neuro-Oncology* made possible by a grant from Schering-Plough.

brain tumors, and several excellent talks brought investigators up to speed with current topics in the field. Thursday afternoon brought concurrent sessions focusing on imaging of brain tumors, the role of the NIH-sponsored Cancer Genome Atlas in the study of brain tumors, and radiation injury and low grade gliomas. These sessions led into a point-counter-point panel discussion of the management of primary and metastatic brain tumors, after which the first group of over 200 posters were available for viewing and discussion.

Saturday again began with three concurrent sunrise sessions devoted to oligodendrogliomas, novel clinical trial design, and brain tumor models, after which a morning plenary session devoted to prognostic markers in brain tumors was held. The morning session concluded with a Keynote Address by Charles Stiles who gave a very nice presentation about the role of olig transcription factors in stem cell biology and brain tumor development. Saturday afternoon brought concurrent sessions focused on immunology-immunotherapy, epidemiology and quality of life, and stem cells-tumor biology. Saturday afternoon also featured the first meeting of the Academic Community Alliance, a group focused on bringing together groups in academia with those in community practice. An additional poster session followed the afternoon concurrent sessions, and led to the SNO banquet Saturday evening.

Sunday morning brought three additional sunrise sessions on micro RNAs, EGFR inhibitors, and the Cancer Genome Atlas, after which Paul Mischel, MD, PhD presented an excellent Farber Lecture describing how the range of genome analysis tools now available will impact the ability of investigators to identify important signaling pathways in brain tumors and use this information for therapeutic benefit. The Farber Lecture was followed by a well-attended session on glioblastoma clinical trials, in which updates on a variety of leading edge trials were presented. The meeting adjourned at noon on Sunday with the hope that all present would be able to attend the next meeting in Las Vegas.
2008 has been a banner year for SNO’s official journal, *Neuro-Oncology*, with gains in the amount of information broadcast to its readers and its influence in the realm of scholarly publishing. As noted in last year’s annual report, these changes are part of an ongoing process initiated by the journal’s management team to meet its long-term goal of providing in-depth analyses of some of the most important questions confronting the neuro-oncology community and to build a databank of state-of-the-art knowledge, all the while remaining sensitive to the diverse needs of its multidisciplinary contributors and readers.

**Impact Factor Rises Again**

In the August 2007 issue of *Neuro-Oncology* (vol. 10, no. 4), Editor-in-Chief W. K. Alfred Yung happily reported the news that the journal’s impact factor (published annually by Thomson Scientific in its Journal Citation Reports) now stands at 5.806, up from 4.939 in 2006. This ranks *Neuro-Oncology* 6th out of 146 clinical neurology journals (up from 14th in 2006), and 16th out of 132 oncology journals (up from 23rd). See the figure for a look at the historical trend. Of interest: The journal now ranks just behind *Clinical Cancer Research* in the oncology journals list and *Neurology* in the neurology journals list, putting it in very good company, indeed.

Dr. Yung took advantage of the journal’s reaching this new milestone to publicly thank the many reviewers who help ensure that the journal continues to grow in stature. While the Editorial Board members are listed each month in the journal’s masthead, many others do their work more quietly behind the scenes. A list of those volunteers who serve the journal in this less obvious but no less crucial function is shown in the sidebar.

### Non-Editorial Board Reviewers for *Neuro-Oncology*

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joachim M. Baehring</td>
<td>Takamitsu Fujimaki</td>
</tr>
<tr>
<td>Lisa M. DeAngelis</td>
<td>Rolf F. Barth</td>
</tr>
<tr>
<td>Patrick Y. Wen</td>
<td>Seiichi Yoshida</td>
</tr>
<tr>
<td>John W. Henson</td>
<td>Jaclyn A. Biegel</td>
</tr>
<tr>
<td>Ian E. McCutcheon</td>
<td>Faith G. Davis</td>
</tr>
<tr>
<td>Lauren E. Abrey</td>
<td>Hiroki Shirato</td>
</tr>
<tr>
<td>John Park</td>
<td>Jay S. Loeffler</td>
</tr>
<tr>
<td>Fred H. Hochberg</td>
<td>Carmine M. Carapella</td>
</tr>
<tr>
<td>Tracy T. Batchelor</td>
<td>Caterina Giannini</td>
</tr>
<tr>
<td>Shingo Takano</td>
<td>Andrew T. Parsa</td>
</tr>
<tr>
<td>Louis Burt Nabors</td>
<td>Francesc Graus</td>
</tr>
<tr>
<td>Howard Colman</td>
<td>Nalin Gupta</td>
</tr>
<tr>
<td>Robert B. Jenkins</td>
<td>Jann N. Sarkaria</td>
</tr>
<tr>
<td>Mitsutoshi Nakada</td>
<td>Graeme Hodgson</td>
</tr>
<tr>
<td>Shiao Y. Woo</td>
<td>Ping Yang</td>
</tr>
<tr>
<td>Jeffrey J. Raizer</td>
<td>Tracy Richmond McKnight</td>
</tr>
<tr>
<td>Hideho Okada</td>
<td>James Rubenstein</td>
</tr>
<tr>
<td>Isa M. Hussain</td>
<td>Joseph C. Loftus</td>
</tr>
<tr>
<td>David Schiff</td>
<td>Robert Rostomily</td>
</tr>
<tr>
<td>Ryuya Yamanaka</td>
<td>Joseph Costello</td>
</tr>
<tr>
<td>Xiang Zhang</td>
<td>Edward Jackson</td>
</tr>
<tr>
<td>Jeffrey S. Wefel</td>
<td>Annette Johnson</td>
</tr>
<tr>
<td>Olivier Chinot</td>
<td>Tena Rosser</td>
</tr>
<tr>
<td>Shiyuan Cheng</td>
<td>Takashi Komori</td>
</tr>
<tr>
<td>Randy Jensen</td>
<td>Yasuo Iwadate</td>
</tr>
<tr>
<td>Riccardo Soffietti</td>
<td>Marios Papadopoulos</td>
</tr>
<tr>
<td>Chunhai (Charlie) Hao</td>
<td>Adam P. Dicker</td>
</tr>
<tr>
<td>Maria G. Castro</td>
<td>Eric L. Chang</td>
</tr>
<tr>
<td>John K. Wiencke</td>
<td>Paul D. Brown</td>
</tr>
<tr>
<td>Vinay K. Puduvali</td>
<td>Graziella Filippini</td>
</tr>
<tr>
<td>Andreas H. Jacobs</td>
<td>Lisa R. Rogers</td>
</tr>
<tr>
<td>Yukihiko Sonoda</td>
<td>Wolfgang Bohn</td>
</tr>
<tr>
<td>Martin J.B. Taphoorn</td>
<td>Kenneth J. Cohen</td>
</tr>
<tr>
<td>Koichi Ichimura</td>
<td>Christopher D. Turner</td>
</tr>
<tr>
<td>Wolfgang Wick</td>
<td>Michael E. Berens</td>
</tr>
<tr>
<td>Alex McMillan</td>
<td>Peter A. Forsyth</td>
</tr>
</tbody>
</table>

*Spotlight on the Journal*
2008 is also notable as the year in which *Neuro-Oncology* made its first leap beyond quarterly publication, moving to a six-times-a-year, bi-monthly schedule. This represents a 50% increase in the number of issues published and translates into about 20 additional high-caliber papers in the neuro-oncology literature per year. It also means that by the end of 2008, the journal will have published roughly 1,000 pages of text, versus just over 600 in 2007.

This change in publication frequency was prompted by several factors, not the least of which is the increased number of high-quality research papers submitted as the impact factor has continued to rise over the last several years. In addition, the growing interest in neuro-oncology and the disciplines related to it has meant increased pressure to get information to the community at a faster rate of speed. In 2007, the journal received 285 new and 68 revised manuscripts; in 2008 (as of Sept. 15), 249 new and 83 revised manuscripts had been received (which would put us on pace to handle about 347 new and 116 revised papers by the end of the year).

Another change the journal has instituted in response to the growing thirst for information is the practice of posting accepted manuscripts online. Because there is a necessary delay in the time between acceptance and print publication, the journal now posts articles to High Wire in two stages. First, the raw copy submitted by the authors and accepted by the editors, which has not yet been laid out or edited by the publisher (Duke University Press), is now being posted online. When the manuscript has been edited by the Press, prepared for print publication, and given a final review by the editorial office and the authors, the raw-copy posting is then replaced by the final, laid-out version that will ultimately appear in print. This change gets much-desired information into the hands of readers more quickly, while still preserving the integrity of the final product.

More changes are anticipated, some obvious (for instance, it is anticipated that the journal will soon move to monthly publication), others less so (for instance, in operational areas). All, however, will be undertaken advisedly, with the readers' and the supporting organizations' interests in mind.
The Society for Neuro-Oncology understands that brain tumors do not recognize geographical boundaries. Unfortunately, in many "third world" areas, the survival rate from brain cancer is a fraction (in some cases one-tenth) of the survival rate in the "developed world". Seeking to promote international clinical and research activities in both pediatric and adult neuro-oncology, our Society announced the launch of the SNO International Outreach Initiative at the 2007 Annual Meeting. With the support of our volunteer leadership, SNO members and our corporate partners, we have had a productive year.

Travel Scholarships

We are pleased to announce that for the first time, SNO has been able to award travel scholarships to the 2008 SNO Annual Scientific Meeting and Education Day. Travel scholarships in the amount of $1,500 each were awarded to applicants in each of the following underserved geographical areas: Central America & the Caribbean, Central and Southern Africa, China & associated countries, Eastern Europe, Far East & Australasia, Indian Sub-Continent, North Africa & the Middle East and South America. To qualify for an award the applicant must be living and working outside the United States and Canada, have a professional focus in neuro-oncology, and be otherwise unable to attend without the benefit of a travel scholarship. Scholarships were awarded based on the applicant’s ability to share the information learned at the SNO meeting and foster neuro-oncology education with their colleagues upon their return to their home country. It is our hope that with the continuing generosity of our members, we will be able to increase the number of scholarships to future meetings.

Access to Neuro-Oncology

Another important element of our international efforts has been to extend the availability of our journal, Neuro-Oncology, through discounted subscriptions to individuals, academic centers and hospitals in countries of low per capita GNP. Developing country membership in the Society includes an electronic-only subscription to our official journal, Neuro-Oncology. Eligibility to receive the discounted developing country rate is dependent on the country’s classification as a "low income" or "lower middle income" country as determined by the Income Report of the World Bank available on the SNO website. Thanks to the support of Fulmer Pharmaceuticals in India, over 100 key professionals in that country are now receiving electronic copies of the journal.

Moving Ahead

With the guidance of the SNO membership and volunteer leaders, we will continue to explore ways to provide educational materials, teaching and training resources as well as information on international fellowships and funding opportunities. We are currently working on a SNO Research Fellowship initiative that we hope will allow a young professional to study in North America for a period of up to three years. Information on all of our current and planned international activities is available in a new section of the SNO website. In the year ahead we seek to build upon the initial progress we have had in 2008, and further expand collaborative relationships with local oncology societies, leading neuro-oncologists, and governmental Ministries of Health.
In keeping with our mission to help nurture clinical and basic science research in neuro-oncology, the Society for Neuro-Oncology is working on several new mentorship initiatives to support and encourage those new to the field.

Grant Review

As you know, our new investigators are finding it increasingly hard to obtain their first peer reviewed funding for clinical or basic research, a trend which in the long-term will have a significant negative impact in furthering new discoveries in neuro-oncology. Many of these young investigators do not have local expertise to provide initial guidance/review of their applications. The main objective of the SNO Grant Review Initiative therefore, is to provide young investigators with guidance from senior volunteer members of SNO who will assist them in obtaining their first peer reviewed funding applications. As a token of appreciation from the Society, an honorarium of $200 from the Victor Levin SNO Foundation Fund is provided to the reviewers. More information on this initiative and grant review forms are available on the SNO website.

SNO Career Center

We have also launched the SNO Career Center, an interactive on-line job board and resource center. Although open to all SNO members, we believe that this site will be especially useful to those new to the field who will use this resource to apply for available positions and fellowship opportunities. More than just a posting of job openings, the SNO Career Center allows users to upload their CV into a searchable database, as well as create job agents that will automatically send email alerts when opportunities matching entered criteria are posted on the site. Employers can also benefit from this new resource with focused and direct access to professionals working in the field of neuro-oncology.

Mentorship

Under the leadership of Lauren Abrey and Susan Chang, we are in the process of developing a formal mentorship program that will be launched at our 2008 meeting in Las Vegas. This initiative will seek to match a young investigator with a senior member of SNO who will then guide him or her throughout the formative stages of their career. The SNO Mentorship Program will be formally launched during a reception at the 2008 SNO meeting in Las Vegas, where young investigators will have the opportunity to meet, network, form new relationships and establish new collaborations. The Society thanks Genentech for providing the support to launch this initiative.
The following financial highlights are presented by management of Society for Neuro Oncology as of June 30, 2007:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$178,000</td>
</tr>
<tr>
<td>Investments</td>
<td>857,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>56,000</td>
</tr>
<tr>
<td>Endowment Assets</td>
<td>176,000</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$1,267,000</strong></td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>55,000</td>
</tr>
<tr>
<td>Net Assets</td>
<td>1,212,000</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$1,267,000</strong></td>
</tr>
</tbody>
</table>

The following financial highlights are presented by management of Society for Neuro Oncology for the fiscal year ended June 30, 2007:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$1,081,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>505,000</td>
</tr>
<tr>
<td><strong>Increase in net assets</strong></td>
<td><strong>$576,000</strong></td>
</tr>
</tbody>
</table>

The financial statements of Society for Neuro Oncology for the fiscal year ended June 30, 2007, were audited by Durio & Company, P.C., Certified Public Accountants. The complete financial statements and Independent Auditor’s Report are available at www.soc-neuro-onc.org.
The following preliminary financial highlights are presented by management of Society for Neuro Oncology as of June 30, 2008:

| Cash and cash equivalents | $ 272,000 |
| Investments | 936,000 |
| Contributions receivable | 19,000 |
| Endowment Assets | 187,000 |
| **Total Assets** | **$ 1,414,000** |
| Total Liabilities | 20,000 |
| **Net Assets** | **1,394,000** |
| **Total Liabilities and Net Assets** | **$ 1,414,000** |

The following preliminary financial highlights are presented by management of Society for Neuro Oncology for the fiscal year ended June 30, 2008:

| Total revenues and other support | $ 877,000 |
| Total program and supporting service expenses | 695,000 |
| **Increase in net assets** | **$ 182,000** |

As of the printing of this Annual Report, the financial statements of Society for Neuro Oncology for the fiscal year ended June 30, 2008, were in the process of being audited by Durio & Company, P.C., Certified Public Accountants. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.soc-neuro-onc.org.
Administrative Staff

Executive Director
J. Charles (Chas) Haynes, J.D.

Chief Administrative Officer
Jan Esenwein

Administration
Linda Greer

Society for Neuro-Oncology
4617 Birch Street
Bellaire TX 77401
tel 713.349.0952
fax 832.201.8129

www.soc-neuro-onc.org
Officer, Board of Directors and Committees

Society for Neuro-Oncology

Officers and Board of Directors

President
Susan M. Chang, MD

Vice President
Frederick F. Lang, MD

Secretary-Treasurer
Lauren E. Abrey, MD

Board of Directors
Kenneth D. Aldape, MD
Timothy F. Cloughesy, MD
Jonathan L. Finlay, MD
Glenn J. Lesser, MD
David N. Louis, MD
Minesh P. Mehta, MD
Christina A. Meyers, PhD
Erwin Van Meir, PhD

Incoming Board Members
Teri S. Armstrong, PhD
Antonio E. Chiocca, MD, PhD
Jonathan L. Finlay, MD
Evanthia Galanis, MD
Russell O. Pieper, PhD
Patrick Y. Wen, MD

Past Presidents
Victor A. Levin, MD
Mitchel S. Berger, MD
Stuart A. Grossman, MD
Edward G. Shaw, MD
Michael D. Prados, MD
Abhijit Guha, MD

Foundation Board
Edward G. Shaw, MD
Victor A. Levin, MD
Mitchel S. Berger, MD

Journal Editor in Chief
WK Alfred Yung, MD

Executive Editor, SNO
C. David James, PhD

Awards Committee
The Awards Committee is charged with developing criteria for SNO awards, annually reviewing award candidates, and forwarding to the Board a list of Awards and award recipients to be honored at the Annual Meeting.
Chair: Kenneth Aldape, MD

Audit Committee
The Audit Committee is a newly formed committee and is composed of a Chair and Vice Chair, the Vice President, the Secretary-Treasurer, the Executive Director, and additional designated members as necessary. The committee has the responsibility of overseeing annual internal audits of Society financial affairs, and conveying an annual report to the President and the Board, who may approve review of the audit by external committees as needed. The committee also advises and makes recommendations to the Board of Directors based on findings of such audits.
Chair: Gene Barnett, MD

Bylaws Committee
The Bylaws Committee reviews the Bylaws at least annually (more frequently as issues arise) and makes recommendations for revision as necessary. Members of this committee shall also review any proposed changes and advise the Board of Directors on proposed revisions.
Chair: Kurt A. Jaeckle, MD
Vice Chair: Ian McCutcheon, MD

Education Committee
The Education Committee advises the Board of Directors on all projects concerning education in the field of neuro-oncology, including planning of the Education Day.
Chair: Patrick Wen, MD
Future Sites Committee
The Future Sites Committee reviews potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue.
Chair: Walter A. Hall, MD
Vice Chair: Lynn Ashby, MD

International Outreach Committee
The International Outreach Committee is another newly formed committee. It is composed of a Chair and Vice-Chair, the President and Vice President of the Society, and other representative International members recommended by the Chair or President, as approved by the Board of Directors. The committee will have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and issues of importance to the international conduct of the Society.
Chair: Jonathan Finlay, MD
Vice Chair: Waldemar Debinski, MD

Membership Committee
The Membership Committee is charged with reviewing and voting on all applicants for membership. Responsibilities include the evaluation of a member’s professional conduct as requested by a majority of the Board of Directors, and development of initiatives to promote membership.
Chair: Larry Kun, MD
Vice Chair: Arnab Chakravarti, MD

Nursing Committee
The Neuro-oncology Nursing Committee is a third new committee. It is composed of a Chair and Vice Chair, and other members who will have the responsibility of advising and making recommendations to the Board of Directors on all projects concerning education and other significant matters related to the field of neuro-oncology nursing. This committee also coordinates educational activities for the nursing membership, including workshops, satellite symposia or special sessions involving neuro-oncology nursing. The committee will coordinate the program for these educational activities in conjunction with the Education and Scientific Program Committees, and such programs will primarily be conducted at the Annual Society or World Federation Meetings.
Chair: Nooren Lahey, MS
Vice Chair: Vanessa Nestor, MS

Publications Committee
The Publications Committee is a fourth new committee and is composed of a Chair and Vice Chair, the Executive Director and Chief Administrative Officer, the Secretary-Treasurer, and Chairs of the Awards and Education Committees. This committee has the responsibility of advising and making recommendations to the Board of Directors on issues pertaining to publications of the Society, including but not limited to the officially-endorsed Journal of the Society.
Chair: Oliver Bogler, PhD
Vice Chair: Daphne Haas-Kogan, MD

Scientific Program Committee
The Scientific Program Committee supervises and coordinates all aspects of upcoming SNO Scientific Meetings, including selection of platform presentations, keynote speakers, expert sessions, and other invited speakers. Members will review meeting evaluations, solicit other comments on meeting structure and organization, and recommend changes as appropriate.
Chair: Michael Vogelbaum, MD, PhD
SNO Partners

Platinum Level
American Brain Tumor Association
EMD Serono
Genentech
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Schering Plough Oncology
Sontag Foundation

Gold Level
AstraZeneca
Bristol-Myers Squibb
CERN Foundation
Eisai

Silver Level
Eli Lilly

Bronze Level
Bradmer Pharmaceuticals
Northwest Biotherapeutics
Tug McGraw Foundation

President’s Club
Dean
Jeffrey S. Brindle, MD
Stanislaw R. Burzynski, MD, PhD
Morris D. Groves, MD, JD
Abhijit Guha, MD
Kevin Murray, MD
Raymond E. Sawaya, MD
Edward G. Shaw, MD
Childhood Brain Tumor Foundation

Professor
Peter McL. Black, MD
Jonathan L. Finlay, MD
Gregory N. Fuller, MD, PhD
John G. Golfinos, MD
Walter A. Hall, MD
Minesh Mehta, MD
Stephen K. Powers, MD
James T. Rutka, MD
Christopher Schultz, MD
Mark E. Shaffrey, MD
Erwin Van Meir, PhD

Associate
Oliver Bögler, PhD
Michael R. Chicoine, MD
Ali K. Choucair, MD
Charles Hesdorffer, MD
Carol Kruchko
Christina A. Meyers, PhD
Elizabeth W. Newcomb, MD
Michael A. Vogelbaum, MD, PhD

Fellow
Jeffrey Allen, MD
Henry Brem, MD
Michael Cusimano, MD
Waldemar Debinski, PhD
Bonnie Feldman
Karen L. Fink, MD, PhD
Alexandra Flowers, MD
Peter A. Forsyth, MD, FRCP C
Henry S. Friedman, MD
Jeffrey Goldman, MD
Robert Jenkins, MD, PhD
Arie Perry, MD
Surasak Phuphanich, MD
Jeffrey Raizer, MD
Gerald Rosen, MD
Adrienne C. Scheck, PhD
Jeffrey W. Sherman, MD
Robert L. Tufel

Victor Levin Founders Society
Mr. and Mrs. Robert Fleishman
Brian L. Greenspun
Victor A. Levin, MD
Harold and Pamela Ruttenberg
Schering-Plough Corporation
WK Alfred Yung, MD

International Outreach
Eric Bouffet, MD
Ali Choucair, MD
Abhijit Guha, MD
Waldemar Debinski, MD, PhD
Fulford India
Jonathan Finlay, MD
Marguerite Sciuk
**Mission**

SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

**Vision**

SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

**SNO Members**

- Neuro-oncology 22%
- Neurosurgery 23%
- Radiation Oncology 15%
- Other 2%
- Pathology 5%
- Associate 6%
- Pediatric Oncology 7%
- Medical Oncology 10%
- Basic Science 10%
- Medical Oncology 10%
Society for Neuro-Oncology
4617 Birch Street
Bellaire TX 77401
tel 713.349.0952
fax 832.201.8129
www.soc-neuro-onc.org